A malaria vaccine has shown promising results in early stage clinical trials, according to researchers. Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses. The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity. The research is published in the journal Science. Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: "We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers."
